Social media shapes how GLP-1 users seek weight-loss advice

What happened

A Coventry University–led study reports that people using GLP-1 weight-loss medications often seek advice from social media and online communities more than from health care professionals.

In the survey, almost half of participants (48%) said social media was a source of information, while health care professionals were consulted less frequently, according to the researchers.

The authors say this pattern matters because these medications can involve side effects and potential misuse, and because people may need support to maintain outcomes over time.

What the evidence shows about social media influence on weight-loss drug users

The evidence comes from a cross-sectional survey study exploring how people in the U.K. are using GLP-1 receptor agonists for weight management, published in BMC Public Health.

Researchers from the U.K. and Canada reported that users of GLP-1 medications—including Ozempic, Wegovy, and Mounjaro—often relied on social media, online forums, and friends and family for information about the drugs.

Study lead Dr. Jason Tallis said, “One of the most striking findings was the extent to which users relied on social media, friends, family and online forums for information, rather than health care professionals,” and pointed to an “important gap in evidence-based support.”

• Study type: cross-sectional survey
• Population described: people in the U.K. using GLP-1 medications for weight management
• Information sources reported: social media, online forums, friends/family; health care professionals less frequently

Why people looked online: side effects, daily tradeoffs, and longer-term worries

Participants reported seeking practical advice on how to handle side effects and long-term concerns, which may help explain why peer communities and social platforms become a frequent reference point.

The survey found high satisfaction, with 93% of users reporting positive effects on body weight and 83% on appearance, but it also surfaced potential challenges: nearly two-thirds (62%) reported skipping meals at least two or three times a week and reduced energy levels that affected physical activity or daily tasks.

More than 46% expressed concerns about the impact of the medications on muscle mass, and participants discussed psychological impacts such as changes in confidence, body image, and eating habits—topics that often attract shared stories and peer support online.

• Reported positives: 93% positive effects on body weight; 83% on appearance
• Reported challenges: 62% skipping meals at least 2–3 times/week and reduced energy affecting activity or daily tasks
• Reported concerns: >46% concerned about muscle mass; common questions on nausea, fatigue, muscle loss, and maintaining weight loss

Practical context for metabolic health: access, checks, and dosing behavior

The study also links the online advice trend to how people access these medications and how they respond when results feel slow or side effects appear.

Researchers found most participants obtained medication through online pharmacies, with some raising concerns about the robustness of preprescription checks.

A small proportion reported taking higher doses or using the medication more frequently than recommended because they felt it was not working effectively; the authors argue this underscores the need for clearer, evidence-based guidance and practical support during use and after stopping treatment.

• Most participants reported obtaining GLP-1 medications through online pharmacies
• Some participants questioned the robustness of preprescription checks
• A small proportion reported higher-than-recommended dosing or more frequent use when they felt it wasn’t working

Limitations and caveats to keep in mind

This study describes self-reported experiences and information sources at one point in time, so it can highlight patterns but cannot show cause and effect between social media use and outcomes.

The findings are described as reflecting how people in the U.K. are using these medications, so readers should be cautious about applying the exact percentages to other countries, health systems, or prescribing rules.

The paper emphasizes the complexity of GLP-1 medications and notes risks such as side effects, misuse, and weight regain after stopping treatment; it also flags a lack of long-term support when people discontinue therapy, as highlighted by Professor David Broom of York St John University.

• Cross-sectional survey: cannot establish causality
• Self-reported responses may not match clinical records
• Applies to surveyed U.K. participants; access and support may differ elsewhere